FFA
CASI

Fragasso Financial Advisors’s CASI Pharmaceuticals CASI Stock Holding History

Fragasso Financial Advisors’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,650
Closed -$13K – 184
2022
Q1 		$13K Buy
+1,650
New +$13K ﹤0.01% 187

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fragasso Financial Advisors's CASI Position: Q2 2022 in Review

Fragasso Financial Advisors sold out of CASI Pharmaceuticals (CASI) in Q2 2022, closing a stake of 1,650 shares — an estimated $13K sold.

Fragasso Financial Advisors first reported a position in CASI in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2022.

  • Fragasso Financial Advisors reported no remaining CASI Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fragasso Financial Advisors sold 1,650 CASI Pharmaceuticals shares in Q2 2022, an estimated $13K.
  • Fragasso Financial Advisors first reported a position in CASI Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Fragasso Financial Advisors's CASI Pharmaceuticals position peaked at $13K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2022.

Based on Fragasso Financial Advisors's 13F filing for Q2 2022, filed 30 Aug 2022.